BiotechTube

Crizotinib + Enzalutamide

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-resistant Prostate Cancer

Conditions

Castration-resistant Prostate Cancer

Trial Timeline

Aug 1, 2014 → Jan 3, 2022

NCT ID
NCT02207504

About Crizotinib + Enzalutamide

Crizotinib + Enzalutamide is a phase 1 stage product being developed by Astellas Pharma for Castration-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02207504. Target conditions include Castration-resistant Prostate Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02207504Phase 1Completed

Competing Products

20 competing products in Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
41
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
EnzalutamideAstellas PharmaPhase 2
52
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaApproved
85
enzalutamideAstellas PharmaPre-clinical
23
Enzalutamide + FlutamideAstellas PharmaPhase 2
52
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
23
EnzalutamideAstellas PharmaApproved
85
EnzalutamideAstellas PharmaPhase 2
52
MDV3100Astellas PharmaPre-clinical
23
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85